Sukumar Nagendran

2022 - Taysha Gene Therapies

In 2022, Sukumar Nagendran earned a total compensation of $1.4M as President and Head of Research and Development at Taysha Gene Therapies.

Compensation breakdown

Option Awards$1,285,910
Salary$23,542
Other$54,093
Total$1,363,545

Nagendran received $1.3M in option awards, accounting for 94% of the total pay in 2022.

Nagendran also received $23.5K in salary and $54.1K in other compensation.

Rankings

In 2022, Sukumar Nagendran's compensation ranked 2,429th out of 5,753 executives tracked by ExecPay. In other words, Nagendran earned more than 57.8% of executives.

ClassificationRankingPercentile
All
2,429
out of 5,753
58th
Division
Manufacturing
1,332
out of 3,133
58th
Major group
Chemicals And Allied Products
600
out of 1,419
58th
Industry group
Drugs
554
out of 1,320
58th
Industry
Biological Products, Except Diagnostic Substances
137
out of 291
53rd
Source: SEC filing on May 8, 2023.

Nagendran's colleagues

We found three more compensation records of executives who worked with Sukumar Nagendran at Taysha Gene Therapies in 2022.

2022

RA Session

Taysha Gene Therapies

Chief Executive Officer

2022

Sean Nolan

Taysha Gene Therapies

Chief Executive Officer

2022

Kamran Alam

Taysha Gene Therapies

Chief Financial Officer

News

In-depth

You may also like